Enrollment completed of Phase 1 Clinical Trial of Captisol-enabled Iohexol

cyclodextrine-captisol — Enrollment completed of Phase 1 Clinical Trial of Captisol-enabled Iohexol

SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces completion of enrollment of the Company’s Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol program. The CE-Iohexol program is designed to develop a Captisol-enabled, next-generation contrast agent for diagnostic imaging with a reduced risk of renal toxicity. Ligand also provides below a summary of the findings of a survey of clinicians on radiocontrast agent selection and use.

A novel oral film of carbomer/Poly(vinyl alcohol)/hydroxypropyl cellulose triple polymer loaded with Periplaneta Americana extract for enhancing the oral ulcer treatment

Formulation and Evaluation of Tamsulosin Hydrochloride Sustained Release Capsules Using Pelletization Technique

The benefits of lactose as an excipient

“We are pleased to announce the progress of CE-Iohexol and look forward to reporting Phase 1 data later this year. This program holds the potential to increase the safety of widely-used commercial contrast agents, and, if successful, provide Ligand later-stage out-licensing opportunities,” said John Higgins, Chief Executive Officer of Ligand. “A key priority of Ligand’s business model is to conduct targeted R&D with the goal of advancing programs to secure significant financial terms upon out-license. Recent market research validates our view that there is a substantial unmet need for safer radiocontrast agents.” Continue reading